IL160700A0 - 3-substituted-4-pyrimidone derivatives - Google Patents
3-substituted-4-pyrimidone derivativesInfo
- Publication number
- IL160700A0 IL160700A0 IL16070002A IL16070002A IL160700A0 IL 160700 A0 IL160700 A0 IL 160700A0 IL 16070002 A IL16070002 A IL 16070002A IL 16070002 A IL16070002 A IL 16070002A IL 160700 A0 IL160700 A0 IL 160700A0
- Authority
- IL
- Israel
- Prior art keywords
- sup
- sub
- substituted
- ring
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001331674 | 2001-09-21 | ||
JP2001331677 | 2001-09-21 | ||
JP2001331675 | 2001-09-21 | ||
JP2001331678 | 2001-09-21 | ||
PCT/JP2002/009685 WO2003037888A1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160700A0 true IL160700A0 (en) | 2004-08-31 |
Family
ID=27482651
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16070002A IL160700A0 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
IL160700A IL160700A (en) | 2001-09-21 | 2004-03-03 | 3-substituted-4-pyrimidone derivatives and medicaments comprising them for the treatment of neurodegenerative disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL160700A IL160700A (en) | 2001-09-21 | 2004-03-03 | 3-substituted-4-pyrimidone derivatives and medicaments comprising them for the treatment of neurodegenerative disease |
Country Status (24)
Country | Link |
---|---|
US (1) | US7427615B2 (de) |
EP (1) | EP1427720B1 (de) |
JP (1) | JP4347050B2 (de) |
KR (1) | KR100881821B1 (de) |
CN (1) | CN100488958C (de) |
AT (1) | ATE424393T1 (de) |
AU (1) | AU2002337499B2 (de) |
BR (1) | BR0212892A (de) |
CA (1) | CA2460121C (de) |
CY (1) | CY1110317T1 (de) |
DE (1) | DE60231414D1 (de) |
DK (1) | DK1427720T3 (de) |
EA (1) | EA007576B1 (de) |
ES (1) | ES2323576T3 (de) |
HU (1) | HUP0401900A3 (de) |
IL (2) | IL160700A0 (de) |
MX (1) | MXPA04002662A (de) |
NO (1) | NO325781B1 (de) |
NZ (1) | NZ531636A (de) |
PL (1) | PL368671A1 (de) |
PT (1) | PT1427720E (de) |
SI (1) | SI1427720T1 (de) |
TW (1) | TWI265164B (de) |
WO (1) | WO2003037888A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI241298B (en) | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
AR036604A1 (es) | 2001-09-21 | 2004-09-22 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona 3-sustituida |
WO2004055007A1 (en) * | 2002-12-16 | 2004-07-01 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
US20040242568A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
US7790736B2 (en) | 2003-08-13 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
CN102134229B (zh) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
TW200621760A (en) | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
ZA200703383B (en) * | 2004-09-29 | 2009-05-27 | Mitsubishi Pharma Corp | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
CN101084198A (zh) * | 2004-10-15 | 2007-12-05 | 阿斯利康(瑞典)有限公司 | 取代的氨基-嘧啶酮及其用途 |
US20090221579A1 (en) * | 2004-10-15 | 2009-09-03 | Jeffrey Scott Albert | Substituted Amino-Compounds and Uses Thereof |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
PL1942898T5 (pl) | 2005-09-14 | 2014-10-31 | Takeda Pharmaceuticals Co | Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
WO2008023239A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
AR064660A1 (es) * | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
MX2010002765A (es) * | 2007-09-14 | 2010-05-19 | Mitsubishi Tanabe Pharma Corp | Derivado de 6-pirimidinil-pirimid-4-ona. |
EA201070366A1 (ru) * | 2007-09-14 | 2010-08-30 | Санофи-Авентис | 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы |
AR076014A1 (es) * | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
WO2011019089A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
EP2464632A1 (de) | 2009-08-13 | 2012-06-20 | Mitsubishi Tanabe Pharma Corporation | Pyrimidonderivate als tau-proteinkinase-1-hemmer |
US20130123281A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
ES2926828T3 (es) | 2014-09-29 | 2022-10-28 | Chemocentryx Inc | Procesos e intermedios en la preparación de antagonistas de C5aR |
US20170202821A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4935631B1 (de) | 1970-12-28 | 1974-09-25 | ||
JPS559099B2 (de) | 1972-08-07 | 1980-03-07 | ||
JPS4935633A (de) | 1972-08-09 | 1974-04-02 | ||
JPS5124008B2 (de) | 1972-08-10 | 1976-07-21 | ||
JPS4935632A (de) | 1972-08-10 | 1974-04-02 | ||
JPS5271481A (en) | 1975-12-10 | 1977-06-14 | Yoshitomi Pharmaceut Ind Ltd | Synthesis of pyridylpyrimidines |
JPS52139085A (en) * | 1976-05-13 | 1977-11-19 | Hokuriku Pharmaceutical | 22allylpiperazine derivative and method for its preparation |
US4507302A (en) * | 1979-03-19 | 1985-03-26 | The Upjohn Company | Method for treating arthritis with 6-aryl pyrimidine compounds |
US4619933A (en) * | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
US4725600A (en) | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
EP0354179B1 (de) | 1988-07-29 | 1994-08-17 | Ciba-Geigy Ag | Thiouracile als Stabilisatoren für chlorhaltige Polymerisate |
EP0911390B1 (de) | 1991-12-06 | 2009-08-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit |
DE4206145A1 (de) | 1992-02-28 | 1993-09-02 | Basf Ag | Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide |
JP3324611B2 (ja) | 1992-07-03 | 2002-09-17 | 三菱化学株式会社 | タウ蛋白質のリン酸化方法 |
JPH06329551A (ja) | 1993-03-22 | 1994-11-29 | Mitsubishi Kasei Corp | アルツハイマー病の予防または治療薬およびそのスクリーニング方法 |
JPH07179442A (ja) * | 1993-10-08 | 1995-07-18 | Sagami Chem Res Center | 4−イミノオキサゾリジン−2−オン誘導体、それらの製造方法、及びそれらを有効成分とする除草剤 |
BR9407799A (pt) * | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
CZ296911B6 (cs) | 1996-12-05 | 2006-07-12 | Amgen Inc. | Substituovaný pyrimidin, jeho pouzití a farmaceutický prostredek na jeho bázi |
US6410729B1 (en) * | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
WO1998024782A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
TWI241298B (en) * | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
EP1261327B1 (de) * | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosin-rezeptor modulatoren |
WO2001070728A1 (en) | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-[nitrogen-heterocyclic]pyrimidone derivatives |
EP1136482A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer |
AR036604A1 (es) | 2001-09-21 | 2004-09-22 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona 3-sustituida |
WO2004055007A1 (en) | 2002-12-16 | 2004-07-01 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
-
2002
- 2002-09-20 MX MXPA04002662A patent/MXPA04002662A/es active IP Right Grant
- 2002-09-20 BR BR0212892-6A patent/BR0212892A/pt not_active Application Discontinuation
- 2002-09-20 JP JP2003540169A patent/JP4347050B2/ja not_active Expired - Fee Related
- 2002-09-20 PL PL02368671A patent/PL368671A1/xx unknown
- 2002-09-20 CA CA2460121A patent/CA2460121C/en not_active Expired - Fee Related
- 2002-09-20 ES ES02772871T patent/ES2323576T3/es not_active Expired - Lifetime
- 2002-09-20 HU HU0401900A patent/HUP0401900A3/hu unknown
- 2002-09-20 PT PT02772871T patent/PT1427720E/pt unknown
- 2002-09-20 IL IL16070002A patent/IL160700A0/xx unknown
- 2002-09-20 CN CNB028184696A patent/CN100488958C/zh not_active Expired - Fee Related
- 2002-09-20 EP EP02772871A patent/EP1427720B1/de not_active Expired - Lifetime
- 2002-09-20 AU AU2002337499A patent/AU2002337499B2/en not_active Ceased
- 2002-09-20 AT AT02772871T patent/ATE424393T1/de active
- 2002-09-20 DE DE60231414T patent/DE60231414D1/de not_active Expired - Lifetime
- 2002-09-20 DK DK02772871T patent/DK1427720T3/da active
- 2002-09-20 WO PCT/JP2002/009685 patent/WO2003037888A1/en active IP Right Grant
- 2002-09-20 NZ NZ531636A patent/NZ531636A/en not_active IP Right Cessation
- 2002-09-20 SI SI200230816T patent/SI1427720T1/sl unknown
- 2002-09-20 EA EA200400453A patent/EA007576B1/ru not_active IP Right Cessation
- 2002-09-20 KR KR1020047004112A patent/KR100881821B1/ko not_active IP Right Cessation
- 2002-09-20 US US10/489,606 patent/US7427615B2/en not_active Expired - Fee Related
- 2002-09-20 TW TW091121655A patent/TWI265164B/zh not_active IP Right Cessation
-
2004
- 2004-03-03 IL IL160700A patent/IL160700A/en not_active IP Right Cessation
- 2004-04-20 NO NO20041600A patent/NO325781B1/no not_active IP Right Cessation
-
2009
- 2009-05-28 CY CY20091100562T patent/CY1110317T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1427720T1 (sl) | 2009-08-31 |
US7427615B2 (en) | 2008-09-23 |
PL368671A1 (en) | 2005-04-04 |
NZ531636A (en) | 2005-11-25 |
ATE424393T1 (de) | 2009-03-15 |
HUP0401900A2 (hu) | 2004-12-28 |
US20050090490A1 (en) | 2005-04-28 |
AU2002337499B2 (en) | 2007-08-23 |
CN100488958C (zh) | 2009-05-20 |
EP1427720B1 (de) | 2009-03-04 |
NO325781B1 (no) | 2008-07-14 |
DE60231414D1 (de) | 2009-04-16 |
KR20040054689A (ko) | 2004-06-25 |
DK1427720T3 (da) | 2009-05-04 |
BR0212892A (pt) | 2004-08-03 |
EA007576B1 (ru) | 2006-12-29 |
JP4347050B2 (ja) | 2009-10-21 |
CN1556804A (zh) | 2004-12-22 |
ES2323576T3 (es) | 2009-07-21 |
WO2003037888A1 (en) | 2003-05-08 |
MXPA04002662A (es) | 2004-11-22 |
KR100881821B1 (ko) | 2009-02-03 |
PT1427720E (pt) | 2009-04-27 |
CA2460121A1 (en) | 2003-05-08 |
EA200400453A1 (ru) | 2004-08-26 |
NO20041600L (no) | 2004-06-16 |
EP1427720A1 (de) | 2004-06-16 |
HUP0401900A3 (en) | 2005-08-29 |
JP2005510506A (ja) | 2005-04-21 |
TWI265164B (en) | 2006-11-01 |
IL160700A (en) | 2009-09-22 |
CY1110317T1 (el) | 2015-01-14 |
CA2460121C (en) | 2010-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160700A0 (en) | 3-substituted-4-pyrimidone derivatives | |
EA200400452A1 (ru) | Производные 3-замещенных 4-пиримидонов | |
NO20053449L (no) | 3-substituerte 4-pyrimidonderivater | |
UA83243C2 (ru) | Соединения, которые ингибируют натриезависимый переносчик глюкозы | |
DE60236851D1 (en) | Pyrimidinmatrixmetalloproteinaseinhibitoren | |
GB2393653A (en) | DNA-PK inhibitors | |
NO20060219L (no) | Forbindelser | |
MY146532A (en) | Thiazole derivative | |
HUP0401478A2 (hu) | Fungicid hatású pirazolil-karboxanilid-származékok | |
JO2668B1 (en) | Isoczazolins for controlling invertebrate insects | |
TW200612920A (en) | Novel imidazolidine derivatives | |
NO20004485D0 (no) | Sykloalkenderivater, deres fremstilling og anvendelse | |
DK1008592T3 (da) | Cykliske amidderivater, som inhiberer cathepsin K | |
TW200609218A (en) | Bicyclic compounds | |
TW200740757A (en) | Carboxamide compound and use of the same | |
EP1211253A4 (de) | Trizyklische dihydrobenzofurane, verfahren zu deren herstellung und mittel | |
KR970021067A (ko) | 1-아지닐-테트라졸리논 | |
EP1674454A4 (de) | Substituiertes 2-amino-[1,2,4]triazolo[1,5-a]pyrimidinderivat und dessen verwendung | |
TW200738679A (en) | Carboxamide compound and use of the same | |
EP1104756A4 (de) | Inhibitoren der biosynthese des brassionosteroides | |
NO983656L (no) | Heterocyklyl-ergolinderivater som 5-HT1A reseptorligander | |
IL157453A0 (en) | Hiv inhibiting n-aminoimidazole derivatives | |
TH102358B (th) | อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3 | |
TH102358A (th) | อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3 | |
TH65446A (th) | อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3 |